Paper Details

  1. Home
  2. Paper Details

Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.

Author: AfenjarKaren, BeckmannMatthias W, BoileauJean-François, CamponeMario, FrescoRodrigo, HarbeckNadia, HelmsHans-Joachim, HuangChiun-Sheng, HurvitzSara A, JungKyung Hae, LinYvonne G, MartinMiguel, SlamonDennis, SparanoJoseph, StroyakovskiyDaniil, SymmansW Fraser, ThompsonAlastair M, ValeroVicente, WildiersHans, XuJin

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This phase 3 trial assessed a neoadjuvant regimen for HER2-positive breast cancer that replaces traditional chemotherapy with targeted treatment, aiming to improve outcomes in patients at risk of relapse or death.
Paper Details　
Original Abstract of the Article :
HER2-targeted treatments have improved outcomes in patients with HER2-positive breast cancer in the neoadjuvant, adjuvant, and metastatic settings; however, some patients remain at risk of relapse or death for many years after treatment of early-stage disease. Therefore, new strategies are needed. W...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1470-2045(17)30716-7

データ提供：米国国立医学図書館（NLM）

A New Approach to Treating HER2-Positive Breast Cancer

The fight against breast cancer is a complex battle that requires innovative strategies. This research delves into the world of HER2-positive breast cancer, a type of breast cancer that involves the HER2 gene, a gene that helps control the growth of cells. The researchers explored a new neoadjuvant regimen for HER2-positive breast cancer that replaces traditional chemotherapy with targeted treatment. This groundbreaking approach aims to improve outcomes for patients with HER2-positive breast cancer, particularly those who remain at risk of relapse or death even after treatment of early-stage disease.

Targeted Therapies Show Promise in Breast Cancer Treatment

This study indicates that targeted therapies hold significant promise for improving outcomes in patients with HER2-positive breast cancer. This promising approach offers hope for a more personalized and effective approach to treating this complex disease. The findings suggest that replacing traditional chemotherapy with targeted treatment may offer a safer and more effective way to manage HER2-positive breast cancer.

Finding the Right Treatment Path: A Camel's Journey

The desert is a vast expanse, full of hidden dangers and opportunities. Similarly, the journey through breast cancer treatment can be daunting. This research guides us toward a new path, a path that utilizes targeted therapies to navigate the complex terrain of HER2-positive breast cancer. This targeted approach is like finding a clear oasis in the desert, offering a safe haven for patients, giving them a better chance to thrive.

Dr.Camel's Conclusion

This research offers a promising new approach to treating HER2-positive breast cancer. By replacing traditional chemotherapy with targeted treatment, researchers hope to improve outcomes for patients and provide a safer and more effective way to manage this challenging disease.

Date :
  1. Date Completed 2018-11-26
  2. Date Revised 2022-04-10
Further Info :

Pubmed ID

29175149

DOI: Digital Object Identifier

10.1016/S1470-2045(17)30716-7

Related Literature

Article Analysis
・Effective treatment of breast cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.